Pulmatrix Stock Performance
| PULM Stock | USD 5.62 0.01 0.18% |
The company holds a Beta of -0.0138, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pulmatrix are expected to decrease at a much lower rate. During the bear market, Pulmatrix is likely to outperform the market. At this point, Pulmatrix has a negative expected return of -0.12%. Please make sure to check Pulmatrix's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Pulmatrix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pulmatrix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
| Begin Period Cash Flow | 20.6 M | |
| Total Cashflows From Investing Activities | -398 K |
Pulmatrix | Build AI portfolio with Pulmatrix Stock |
Pulmatrix Relative Risk vs. Return Landscape
If you would invest 650.00 in Pulmatrix on April 28, 2025 and sell it today you would lose (88.00) from holding Pulmatrix or give up 13.54% of portfolio value over 90 days. Pulmatrix is currently does not generate positive expected returns and assumes 4.9067% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Pulmatrix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pulmatrix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pulmatrix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pulmatrix, and traders can use it to determine the average amount a Pulmatrix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0236
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PULM |
Estimated Market Risk
| 4.91 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pulmatrix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pulmatrix by adding Pulmatrix to a well-diversified portfolio.
Pulmatrix Fundamentals Growth
Pulmatrix Stock prices reflect investors' perceptions of the future prospects and financial health of Pulmatrix, and Pulmatrix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pulmatrix Stock performance.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (5.07) % | ||||
| Current Valuation | 11 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.87 X | ||||
| Price To Sales | 10.69 X | ||||
| Revenue | 7.81 M | ||||
| EBITDA | (6.71 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 996 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 1.96 X | ||||
| Cash Flow From Operations | (10.72 M) | ||||
| Earnings Per Share | (3.35) X | ||||
| Total Asset | 9.94 M | ||||
| Retained Earnings | (297.16 M) | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
About Pulmatrix Performance
By examining Pulmatrix's fundamental ratios, stakeholders can obtain critical insights into Pulmatrix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Pulmatrix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.Things to note about Pulmatrix performance evaluation
Checking the ongoing alerts about Pulmatrix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pulmatrix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pulmatrix generated a negative expected return over the last 90 days | |
| Pulmatrix has high historical volatility and very poor performance | |
| Pulmatrix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.81 M. Net Loss for the year was (9.56 M) with profit before overhead, payroll, taxes, and interest of 1.89 M. | |
| Pulmatrix currently holds about 42.91 M in cash with (10.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pulmatrix has a frail financial position based on the latest SEC disclosures |
- Analyzing Pulmatrix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pulmatrix's stock is overvalued or undervalued compared to its peers.
- Examining Pulmatrix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pulmatrix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pulmatrix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pulmatrix's stock. These opinions can provide insight into Pulmatrix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.